Onyx Pharmaceuticals IncNASDAQ:ONXX

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentation of data highlighting Kyprolis(R) (carfilzomib) for Injection, a second-generation proteasome inhibitor, and oprozomib, an oral proteasome inhibitor in early development, at the 18th Congress of the European Hematology Association (EHA) Annual Meeting, June 13-16, 2013 in Stockholm, Sweden.

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentations of data highlighting Nexavar(R) (sorafenib) tablets, Kyprolis(R) (carfilzomib) for Injection, and Stivarga(R) (regorafenib) tablets across a range of cancers. These presentations will take place at the 49th American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, 2013, in Chicago, IL.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the factor that most influences their prescribing decisions for relapsed/refractory multiple myeloma, and that increased overall survival is associated with the highest level of unmet need. Interviewed thought leaders are optimistic that the CRd regimen-- carfilzomib (Onyx Pharmaceuticals/Ono Pharmaceutical's Kyprolis) in combination with lenalidomide (Celgene's Revlimid) and dexamethasone--will show advantages over sales-leading lenalidomide plus dexamethasone (the Rd regimen) on this attribute in the ongoing Phase III ASPIRE trial.